2025 Q3 -tulosraportti
56 päivää sitten36 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 18.2.2025 | |
| 2024 Q3 -tulosraportti | 6.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4.12.2025I have never seen a fall like this - before BTA has even come up for sale. I have experienced similar and larger falls subsequent to the issue in some shares - but never this. Today's lowest price is even below the discount price for the guarantors.
·4.12.2025Very sharp fall, especially since the issue is fully guaranteed..·4.12.2025BioStock: Medivir: ”With this combination, we are at the forefront” Close 21 Nov. 08:23 ∙ MFN Medivir is currently carrying out a fully guaranteed rights issue of approximately 151 million kronor, which runs until December 2. Medivir's CEO Jens Lindberg and Dr. Pia Baumann, Medical Director, visited BioStock's studio to discuss the purpose of the capital raise and the path to a clinical phase II study in collaboration with the Korean Cancer Study Group. We also learn more about partnership opportunities, how fostrox differs from competing alternatives, and about the recently completed license deal regarding remetinostat. See the interview at biostock.se: Medivir: "With this combination, we are at the forefront" This is a press release from BioStock -
·24.11.2025Competing trials for Fostrox part 1 Some thoughts regarding upcoming study results in HCC second line. Refers to all studies except "rechallenge" of immunotherapy which has had difficulty showing good results in other cancer types. Nevertheless, there are quite a few such studies in the coming years, but I see it as proof that there is a lack of other treatment options in HCC second line and many are doing a lot to find a solution due to market demand. Below is a confirmation of what CMO Pia Baumann says in yesterday's Biostock interview, that Medivir is first in line. https://biostock.se/2025/11/medivir-med-den-har-kombinationen-ligger-vi-langst-fram-i-utvecklingen/ -----------2025 Virogin with Chinese CBNG was supposed to report on a second line fas1a/b in Dec24 for VG161 (intratumoral injection - tricky sometimes) but recruitment still seems to be ongoing. Some data has however been reported for 34 patients with ORR of 17.6% (fostrox 2a, 24%), Desease Control Rate (DCR) 64.7% (fostrox 2a, 81%), mOS Overall Survival 9.4 months (fostrox 2a, 13.7 months). In October 2025, Polaris was finished with phase 3 in second line HCC. Relatively strange study where ADI-peg20 is tested vs placebo and the study group consists of arginine-high patients. Nothing published yet. In December 25, Eutilix second line phase 1 with EU-307 TCell concludes. Small study to monitor going forward. In December, Virogin Ltd is to conclude a phase 2a with several cohorts in second line. Given that recruitment is still ongoing, it will probably be delayed. The oncolytic virus VG161 is tested, among other things, mono, the rest is rechallenge. The study is rubricated as 2a/2b but nothing in the study description indicates anything other than just 2a. Virogin Ltd also concludes a fas1 study in second line, now partly with VG2025 mono. ------2026 In June 26, Tvardi reports preliminary results from its partially second-line phase 1/2a for TT1-101 (a small molecule targeting Stat3) as mono. In July 26 comes the next study in second line, Iterion. In the first part of the study (n=22), they tested their molecule Tegavivint which generally only gave ORR of 11% but 25% in a special mutation (ɓ-catenin). The study continues with combos with cabozantinib and levantinib. Here it seems worthwhile to keep an eye open for the rest of the study in phase 2a. A potential 2b could be ready late 28. In June 26, Zhejiang University concludes its second-line phase 1 with CTO180 cells. In July 26, another ph2 study second line will come at SunYat in China. It is a TKI (fruquintinib) so it is likely that results similar to Lenvatinib mono will be obtained. It remains to be seen if they continue. In Aug26, Zhejiang Haichang Biotech launches preliminary phase 2a in second-line regarding WG0301 infusion in combo with Sorafenib. In October 26, Can-Fite BioPharma also concludes (one year delayed) its second-line phase 3 study of naomdenson against placebo against a subpopulation of particularly severe HCC patients with ChildPugh class B7 cirrhosis (LIVERATION). Phase two was not impressive. In December 26, preliminary results second-line phase 1 will come from National Cancer Institute with a CAR-T cell plus fludarabine&psyclophosphamide. Peking University is also finished with a second-line phase 1 with MTS105 (mRNA-LNP). Directly liver-targeted. Worth following going forward. In December 26, Eureka concludes its second line phase 2a with CAR-T targeted at Gpc3. It is the most advanced study of Gpc3. A phase 2b should be ready early/mid 29.·24.11.2025Part 2 In December 26, Eureka concludes its second line phase 2a with CAR-T targeting Gpc3. It is the most advanced study of Gpc3. A phase 2b should be ready early/mid 29. Also Zhenjiang Haichan China concludes a second line phase 2 (single arm) in December 2026 with an antisense oligo WGI-0301 and sorafenib. A possible phase 2b ready early/mid 29 - the question is whether they then continue with sorafenib? In December 26, Renji Hospital concludes a second line phase 1 with T-cell therapy Also Orcicell concludes a phase 1 in second line T cells in December 26. ------------2027 In March 27, Zhejiang concludes an early ph 1 in second line with Cg102-12c. Towards mid-2027, Korean Cancer Group / MEDIVIR concludes its randomized phase 2 in second line. A convincing result can, with some luck and skill, lead to an Accelerated Approval from FDA but the probability is higher that a phase 3 will be initiated which could be ready by the end of 2029. During June 27, Tvardi concludes the second line phase 2 study. Cohort A with Tt1-101 mono . A possible 2b could be ready mid/late 29. In July 27, Zheijang University receives preliminary data on its second line phase 1 with CAR-T-cell anti GPC. In July 27, Zheijang University preliminary data on its second line phase 1 with Neo Vac T01 In Oct 27, Zheijang Unviversity has conclusion of its second line phase 1 anti GPC3 CAR-T. In Oct 27, Alnylam has readout of second-line phase 1 in abn bcat mono. In Oct 27, Sotio reads out its CAR-gpc3 T- cells in second line phase 1. Also Zheijang University a second line ph1 with CAR-gpc3 T- cells. National Cancer Institute reads out in Dec 27 its second line phase 1 with CAR-T cell plus fludarabine&psyclophosphamide finally. In Dec 27, Chinese University in HK concludes its second line phase 2a with cobozantinib. Probably similar to Lenvatinib --------------2028 In Oct28, Shenzeng has final readout of its second line phase 1 with CAR-T GPC3 cells. In Jul29, Zheijang University receives final data on its second line phase 1 with Neo Vac T01 ---------------- During the rest of 2029 until the end of 2042, 7 second line phase 1 studies are concluded, where the majority are CAR-T GPC3 studies, all viewed from November 2025. Statistics 29 non-rechallenge - 5 indicate preliminary results that have final results before 2030 => 24 studies total CONCLUSION Medivir's Fostrox is first in line Closest in line after Korean Cancer Group/Medivir is Virogin Biotech with VG161 which is delayed in a phase 2a evaluating the oncolytic virus Vg161. Virogen 2a data will likely come in Q1 2026. In addition, Iterion and Tvardi should be followed going forward. Now, before FE, I feel content - a good molecule, a good upcoming study with good chances and a good competitive situation in a large market with great medical need.- ·10.11.2025I have done as I usually do. I have sold all my shares (except for a very few) and sold them at a large loss compared to the purchase price. Then I use the money afterwards to buy new shares in the emission - even if they are a bit more expensive (a couple of øre) than what I could buy shares for today - and a bit more expensive than those I just sold. In that way, I support the emission - and support the company's further development of the medicine. I encourage everyone to use the same method. It costs so little, but there is perspective in it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
56 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4.12.2025I have never seen a fall like this - before BTA has even come up for sale. I have experienced similar and larger falls subsequent to the issue in some shares - but never this. Today's lowest price is even below the discount price for the guarantors.
- ·4.12.2025Very sharp fall, especially since the issue is fully guaranteed..·4.12.2025BioStock: Medivir: ”With this combination, we are at the forefront” Close 21 Nov. 08:23 ∙ MFN Medivir is currently carrying out a fully guaranteed rights issue of approximately 151 million kronor, which runs until December 2. Medivir's CEO Jens Lindberg and Dr. Pia Baumann, Medical Director, visited BioStock's studio to discuss the purpose of the capital raise and the path to a clinical phase II study in collaboration with the Korean Cancer Study Group. We also learn more about partnership opportunities, how fostrox differs from competing alternatives, and about the recently completed license deal regarding remetinostat. See the interview at biostock.se: Medivir: "With this combination, we are at the forefront" This is a press release from BioStock -
- ·24.11.2025Competing trials for Fostrox part 1 Some thoughts regarding upcoming study results in HCC second line. Refers to all studies except "rechallenge" of immunotherapy which has had difficulty showing good results in other cancer types. Nevertheless, there are quite a few such studies in the coming years, but I see it as proof that there is a lack of other treatment options in HCC second line and many are doing a lot to find a solution due to market demand. Below is a confirmation of what CMO Pia Baumann says in yesterday's Biostock interview, that Medivir is first in line. https://biostock.se/2025/11/medivir-med-den-har-kombinationen-ligger-vi-langst-fram-i-utvecklingen/ -----------2025 Virogin with Chinese CBNG was supposed to report on a second line fas1a/b in Dec24 for VG161 (intratumoral injection - tricky sometimes) but recruitment still seems to be ongoing. Some data has however been reported for 34 patients with ORR of 17.6% (fostrox 2a, 24%), Desease Control Rate (DCR) 64.7% (fostrox 2a, 81%), mOS Overall Survival 9.4 months (fostrox 2a, 13.7 months). In October 2025, Polaris was finished with phase 3 in second line HCC. Relatively strange study where ADI-peg20 is tested vs placebo and the study group consists of arginine-high patients. Nothing published yet. In December 25, Eutilix second line phase 1 with EU-307 TCell concludes. Small study to monitor going forward. In December, Virogin Ltd is to conclude a phase 2a with several cohorts in second line. Given that recruitment is still ongoing, it will probably be delayed. The oncolytic virus VG161 is tested, among other things, mono, the rest is rechallenge. The study is rubricated as 2a/2b but nothing in the study description indicates anything other than just 2a. Virogin Ltd also concludes a fas1 study in second line, now partly with VG2025 mono. ------2026 In June 26, Tvardi reports preliminary results from its partially second-line phase 1/2a for TT1-101 (a small molecule targeting Stat3) as mono. In July 26 comes the next study in second line, Iterion. In the first part of the study (n=22), they tested their molecule Tegavivint which generally only gave ORR of 11% but 25% in a special mutation (ɓ-catenin). The study continues with combos with cabozantinib and levantinib. Here it seems worthwhile to keep an eye open for the rest of the study in phase 2a. A potential 2b could be ready late 28. In June 26, Zhejiang University concludes its second-line phase 1 with CTO180 cells. In July 26, another ph2 study second line will come at SunYat in China. It is a TKI (fruquintinib) so it is likely that results similar to Lenvatinib mono will be obtained. It remains to be seen if they continue. In Aug26, Zhejiang Haichang Biotech launches preliminary phase 2a in second-line regarding WG0301 infusion in combo with Sorafenib. In October 26, Can-Fite BioPharma also concludes (one year delayed) its second-line phase 3 study of naomdenson against placebo against a subpopulation of particularly severe HCC patients with ChildPugh class B7 cirrhosis (LIVERATION). Phase two was not impressive. In December 26, preliminary results second-line phase 1 will come from National Cancer Institute with a CAR-T cell plus fludarabine&psyclophosphamide. Peking University is also finished with a second-line phase 1 with MTS105 (mRNA-LNP). Directly liver-targeted. Worth following going forward. In December 26, Eureka concludes its second line phase 2a with CAR-T targeted at Gpc3. It is the most advanced study of Gpc3. A phase 2b should be ready early/mid 29.·24.11.2025Part 2 In December 26, Eureka concludes its second line phase 2a with CAR-T targeting Gpc3. It is the most advanced study of Gpc3. A phase 2b should be ready early/mid 29. Also Zhenjiang Haichan China concludes a second line phase 2 (single arm) in December 2026 with an antisense oligo WGI-0301 and sorafenib. A possible phase 2b ready early/mid 29 - the question is whether they then continue with sorafenib? In December 26, Renji Hospital concludes a second line phase 1 with T-cell therapy Also Orcicell concludes a phase 1 in second line T cells in December 26. ------------2027 In March 27, Zhejiang concludes an early ph 1 in second line with Cg102-12c. Towards mid-2027, Korean Cancer Group / MEDIVIR concludes its randomized phase 2 in second line. A convincing result can, with some luck and skill, lead to an Accelerated Approval from FDA but the probability is higher that a phase 3 will be initiated which could be ready by the end of 2029. During June 27, Tvardi concludes the second line phase 2 study. Cohort A with Tt1-101 mono . A possible 2b could be ready mid/late 29. In July 27, Zheijang University receives preliminary data on its second line phase 1 with CAR-T-cell anti GPC. In July 27, Zheijang University preliminary data on its second line phase 1 with Neo Vac T01 In Oct 27, Zheijang Unviversity has conclusion of its second line phase 1 anti GPC3 CAR-T. In Oct 27, Alnylam has readout of second-line phase 1 in abn bcat mono. In Oct 27, Sotio reads out its CAR-gpc3 T- cells in second line phase 1. Also Zheijang University a second line ph1 with CAR-gpc3 T- cells. National Cancer Institute reads out in Dec 27 its second line phase 1 with CAR-T cell plus fludarabine&psyclophosphamide finally. In Dec 27, Chinese University in HK concludes its second line phase 2a with cobozantinib. Probably similar to Lenvatinib --------------2028 In Oct28, Shenzeng has final readout of its second line phase 1 with CAR-T GPC3 cells. In Jul29, Zheijang University receives final data on its second line phase 1 with Neo Vac T01 ---------------- During the rest of 2029 until the end of 2042, 7 second line phase 1 studies are concluded, where the majority are CAR-T GPC3 studies, all viewed from November 2025. Statistics 29 non-rechallenge - 5 indicate preliminary results that have final results before 2030 => 24 studies total CONCLUSION Medivir's Fostrox is first in line Closest in line after Korean Cancer Group/Medivir is Virogin Biotech with VG161 which is delayed in a phase 2a evaluating the oncolytic virus Vg161. Virogen 2a data will likely come in Q1 2026. In addition, Iterion and Tvardi should be followed going forward. Now, before FE, I feel content - a good molecule, a good upcoming study with good chances and a good competitive situation in a large market with great medical need.
- ·10.11.2025I have done as I usually do. I have sold all my shares (except for a very few) and sold them at a large loss compared to the purchase price. Then I use the money afterwards to buy new shares in the emission - even if they are a bit more expensive (a couple of øre) than what I could buy shares for today - and a bit more expensive than those I just sold. In that way, I support the emission - and support the company's further development of the medicine. I encourage everyone to use the same method. It costs so little, but there is perspective in it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 18.2.2025 | |
| 2024 Q3 -tulosraportti | 6.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
56 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 18.2.2025 | |
| 2024 Q3 -tulosraportti | 6.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4.12.2025I have never seen a fall like this - before BTA has even come up for sale. I have experienced similar and larger falls subsequent to the issue in some shares - but never this. Today's lowest price is even below the discount price for the guarantors.
- ·4.12.2025Very sharp fall, especially since the issue is fully guaranteed..·4.12.2025BioStock: Medivir: ”With this combination, we are at the forefront” Close 21 Nov. 08:23 ∙ MFN Medivir is currently carrying out a fully guaranteed rights issue of approximately 151 million kronor, which runs until December 2. Medivir's CEO Jens Lindberg and Dr. Pia Baumann, Medical Director, visited BioStock's studio to discuss the purpose of the capital raise and the path to a clinical phase II study in collaboration with the Korean Cancer Study Group. We also learn more about partnership opportunities, how fostrox differs from competing alternatives, and about the recently completed license deal regarding remetinostat. See the interview at biostock.se: Medivir: "With this combination, we are at the forefront" This is a press release from BioStock -
- ·24.11.2025Competing trials for Fostrox part 1 Some thoughts regarding upcoming study results in HCC second line. Refers to all studies except "rechallenge" of immunotherapy which has had difficulty showing good results in other cancer types. Nevertheless, there are quite a few such studies in the coming years, but I see it as proof that there is a lack of other treatment options in HCC second line and many are doing a lot to find a solution due to market demand. Below is a confirmation of what CMO Pia Baumann says in yesterday's Biostock interview, that Medivir is first in line. https://biostock.se/2025/11/medivir-med-den-har-kombinationen-ligger-vi-langst-fram-i-utvecklingen/ -----------2025 Virogin with Chinese CBNG was supposed to report on a second line fas1a/b in Dec24 for VG161 (intratumoral injection - tricky sometimes) but recruitment still seems to be ongoing. Some data has however been reported for 34 patients with ORR of 17.6% (fostrox 2a, 24%), Desease Control Rate (DCR) 64.7% (fostrox 2a, 81%), mOS Overall Survival 9.4 months (fostrox 2a, 13.7 months). In October 2025, Polaris was finished with phase 3 in second line HCC. Relatively strange study where ADI-peg20 is tested vs placebo and the study group consists of arginine-high patients. Nothing published yet. In December 25, Eutilix second line phase 1 with EU-307 TCell concludes. Small study to monitor going forward. In December, Virogin Ltd is to conclude a phase 2a with several cohorts in second line. Given that recruitment is still ongoing, it will probably be delayed. The oncolytic virus VG161 is tested, among other things, mono, the rest is rechallenge. The study is rubricated as 2a/2b but nothing in the study description indicates anything other than just 2a. Virogin Ltd also concludes a fas1 study in second line, now partly with VG2025 mono. ------2026 In June 26, Tvardi reports preliminary results from its partially second-line phase 1/2a for TT1-101 (a small molecule targeting Stat3) as mono. In July 26 comes the next study in second line, Iterion. In the first part of the study (n=22), they tested their molecule Tegavivint which generally only gave ORR of 11% but 25% in a special mutation (ɓ-catenin). The study continues with combos with cabozantinib and levantinib. Here it seems worthwhile to keep an eye open for the rest of the study in phase 2a. A potential 2b could be ready late 28. In June 26, Zhejiang University concludes its second-line phase 1 with CTO180 cells. In July 26, another ph2 study second line will come at SunYat in China. It is a TKI (fruquintinib) so it is likely that results similar to Lenvatinib mono will be obtained. It remains to be seen if they continue. In Aug26, Zhejiang Haichang Biotech launches preliminary phase 2a in second-line regarding WG0301 infusion in combo with Sorafenib. In October 26, Can-Fite BioPharma also concludes (one year delayed) its second-line phase 3 study of naomdenson against placebo against a subpopulation of particularly severe HCC patients with ChildPugh class B7 cirrhosis (LIVERATION). Phase two was not impressive. In December 26, preliminary results second-line phase 1 will come from National Cancer Institute with a CAR-T cell plus fludarabine&psyclophosphamide. Peking University is also finished with a second-line phase 1 with MTS105 (mRNA-LNP). Directly liver-targeted. Worth following going forward. In December 26, Eureka concludes its second line phase 2a with CAR-T targeted at Gpc3. It is the most advanced study of Gpc3. A phase 2b should be ready early/mid 29.·24.11.2025Part 2 In December 26, Eureka concludes its second line phase 2a with CAR-T targeting Gpc3. It is the most advanced study of Gpc3. A phase 2b should be ready early/mid 29. Also Zhenjiang Haichan China concludes a second line phase 2 (single arm) in December 2026 with an antisense oligo WGI-0301 and sorafenib. A possible phase 2b ready early/mid 29 - the question is whether they then continue with sorafenib? In December 26, Renji Hospital concludes a second line phase 1 with T-cell therapy Also Orcicell concludes a phase 1 in second line T cells in December 26. ------------2027 In March 27, Zhejiang concludes an early ph 1 in second line with Cg102-12c. Towards mid-2027, Korean Cancer Group / MEDIVIR concludes its randomized phase 2 in second line. A convincing result can, with some luck and skill, lead to an Accelerated Approval from FDA but the probability is higher that a phase 3 will be initiated which could be ready by the end of 2029. During June 27, Tvardi concludes the second line phase 2 study. Cohort A with Tt1-101 mono . A possible 2b could be ready mid/late 29. In July 27, Zheijang University receives preliminary data on its second line phase 1 with CAR-T-cell anti GPC. In July 27, Zheijang University preliminary data on its second line phase 1 with Neo Vac T01 In Oct 27, Zheijang Unviversity has conclusion of its second line phase 1 anti GPC3 CAR-T. In Oct 27, Alnylam has readout of second-line phase 1 in abn bcat mono. In Oct 27, Sotio reads out its CAR-gpc3 T- cells in second line phase 1. Also Zheijang University a second line ph1 with CAR-gpc3 T- cells. National Cancer Institute reads out in Dec 27 its second line phase 1 with CAR-T cell plus fludarabine&psyclophosphamide finally. In Dec 27, Chinese University in HK concludes its second line phase 2a with cobozantinib. Probably similar to Lenvatinib --------------2028 In Oct28, Shenzeng has final readout of its second line phase 1 with CAR-T GPC3 cells. In Jul29, Zheijang University receives final data on its second line phase 1 with Neo Vac T01 ---------------- During the rest of 2029 until the end of 2042, 7 second line phase 1 studies are concluded, where the majority are CAR-T GPC3 studies, all viewed from November 2025. Statistics 29 non-rechallenge - 5 indicate preliminary results that have final results before 2030 => 24 studies total CONCLUSION Medivir's Fostrox is first in line Closest in line after Korean Cancer Group/Medivir is Virogin Biotech with VG161 which is delayed in a phase 2a evaluating the oncolytic virus Vg161. Virogen 2a data will likely come in Q1 2026. In addition, Iterion and Tvardi should be followed going forward. Now, before FE, I feel content - a good molecule, a good upcoming study with good chances and a good competitive situation in a large market with great medical need.
- ·10.11.2025I have done as I usually do. I have sold all my shares (except for a very few) and sold them at a large loss compared to the purchase price. Then I use the money afterwards to buy new shares in the emission - even if they are a bit more expensive (a couple of øre) than what I could buy shares for today - and a bit more expensive than those I just sold. In that way, I support the emission - and support the company's further development of the medicine. I encourage everyone to use the same method. It costs so little, but there is perspective in it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt